Internal Medicine

The first-in-class monoclonal antibody is the first therapeutic expansion for this patient population in over 10 years.

Researchers report antibody responses in kidney transplant recipients and the impact of specific regiments utilized by select patients.

Previous research has shown that COVID-19 can impact ocular health.

The FDA approved selexipag tablets for PAH in 2015.

Studies are needed to determine the best treatment regimen for these patients.

OCTA can be used as a support technique to improve patient flow and reduce number of fluorescein angiography.

Treatment was associated with reductions in IGA scores as well as inflammatory and non-inflammatory lesion counts.

The priorities established by a panel of experts are designed to improve efficacy and equity in kidney research and care.

A co-located model of care may be highly beneficial in easing the transition from pediatric to adult care.

The company expects to continue to study the potential inflammatory bowel disease treatment.

The selective topical PDE4 inhibitor demonstrated rapid improvements in IGA and EASI scores and high tolerability in pediatric populations.

Patients with IBD, rheumatoid arthritis, and psoriasis are commonly treated using biologic agents such as infliximab, tofacitinib, and ustekinumab.

On the latest Derm Discussions, Brett King, MD, PhD, joins Brad Glick, DO, to discuss the potential of the JAK inhibitor class for dermatology.

Exenatide extended-release represents the first regulatory approval for a once-weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) for pediatric patients with type 2 diabetes.

Males and patients with higher disease severity were more likely to attend program sessions.

More research is needed to understand the pathogenesis underlying this association.

While investigators did not meet their primary endpoint in the study, results in former smokers within the trial were promising and prompted further research on the subgroup.

The FDA will also not meet the PDUFA date for tofacitinib for the treatment of active ankylosing spondylitis.

Gastrointestinal infections were the most common serious infections associated with biologics, according to a cohort analysis.

The rare liver disease can often lead to liver failure.

A study notes that irradiation did not impact transfusion requirements or relevant laboratory values among patients receiving chronic blood transfusions.

More randomized controlled trials are needed to assess their long-term effectiveness, safety, and effects on health-related quality of life.

In a single-center study, no patients were screened annually for HIV and HCV.

The treatment met all 5 primary efficacy endpoints as part of the ASCEND program.

This patient group was at an increased risk for future exposure to systemic corticosteroids and anti-TNF biologics.